Search results for "Random"

showing 10 items of 3931 documents

Infant Formula Feeding Increases Hepatic Cholesterol 7α Hydroxylase (CYP7A1) Expression and Fecal Bile Acid Loss in Neonatal Piglets.

2018

BACKGROUND: During the postnatal feeding period, formula-fed infants have higher cholesterol synthesis rates and lower circulating cholesterol concentrations than their breastfed counterparts. Although this disparity has been attributed to the uniformly low dietary cholesterol content of typical infant formulas, little is known of the underlying mechanisms associated with this altered cholesterol metabolism phenotype. OBJECTIVE: We aimed to determine the molecular etiology of diet-associated changes in early-life cholesterol metabolism with the use of a postnatal piglet feeding model. METHODS: Two-day-old male and female White-Dutch Landrace piglets were fed either sow milk (Sow group) or d…

0301 basic medicineMalemedicine.medical_specialtymedicine.drug_classSwineMedicine (miscellaneous)030209 endocrinology & metabolismCholesterol 7 alpha-hydroxylaseReal-Time Polymerase Chain ReactionGene Expression Regulation EnzymologicBile Acids and Salts03 medical and health scienceschemistry.chemical_compoundFecesRandom Allocation0302 clinical medicineBlood serumInternal medicinemedicineAnimalsHumansCholesterol 7-alpha-HydroxylaseEnterohepatic circulationNutrition and DieteticsBile acidCholesterolReverse Transcriptase Polymerase Chain ReactionInfantFGF19Infant Formula030104 developmental biologyEndocrinologyMilkchemistryInfant formulaAnimals NewbornLiverFemaleSoybeansNutrient Physiology Metabolism and Nutrient-Nutrient InteractionsBreast feedingThe Journal of nutrition
researchProduct

Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin.

1993

Since 1972, a large number of studies have shown that intravesical treatment with doxorubicin (adriamycin) is effective against carcinoma in situ and multiple papillary tumors. Furthermore, it significantly reduces the recurrence rate after transurethral resection. Its efficacy has been compared with that of Bacillus Calmette-Guerin (BCG), which is the only treatment accepted by the US Food and Drug Administration for therapy of carcinoma in situ (Tis). In more recent years, a few studies have been performed using intravesical epirubicin in the hope that different properties of the molecule might enhance the activity of the anthracyclines, but produce fewer and milder side-effects. After we…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyUrologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicineHumansPharmacology (medical)DoxorubicinEpirubicinPharmacologyChemotherapyUrinary bladderbusiness.industryCarcinoma in situCancermedicine.diseaseSurgeryInfectious Diseasesmedicine.anatomical_structureAdministration IntravesicalOncologyUrinary Bladder NeoplasmsDoxorubicin030220 oncology & carcinogenesisChemoprophylaxisbusinessCarcinoma in SituEpirubicinmedicine.drugJournal of chemotherapy (Florence, Italy)
researchProduct

Can a Prebiotic Formulation Reduce Frailty Levels in Older People?

2019

Objective: The purpose of this study was to examine whether a prebiotic formulation reduces frailty index (FI) levels in older people. Design: We conducted secondary analysis of a placebo-controlled, randomized, double-blind design study. Setting/Participants: The study included non-demented people over the age of 65 who were living in nursing homes and were able to walk. Fifty participants completed the study (75.3±7.3 years, 70% females). Intervention: Participants were randomly assigned to either a group who received daily Darmocare Pre® (inulin and fructooligosaccharides) for 13 weeks or a placebo group (maltodextrin). Measurement: The primary outcome in this secondary analysis was chan…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatmentFrail ElderlyFrailty IndexOligosaccharidesPlacebo grouplaw.invention03 medical and health sciencesPrimary outcomeRandomized controlled trialDouble-Blind MethodlawSecondary analysismedicineHumansAgedAged 80 and overFrailtybusiness.industryPrebioticInulinGeneral Medicine030104 developmental biologyPrebioticsTreatment OutcomePhysical therapyFemalebusinessOlder peopleNursing homesThe Journal of frailtyaging
researchProduct

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

2019

Background Time in therapeutic range (TTR) measures the quality of vitamin K antagonist (VKA) anticoagulation. In patients with atrial fibrillation, the dichotomized SAMe-TT2-R2 score (≥2 vs. < 2 points) can predict if adequate TTR is unlikely to be achieved. Aims We validated the SAMe-TT2-R2 score in patients with venous thromboembolism (VTE) randomized to the warfarin arm of the Hokusai-VTE trial. Patients and Methods A total of 3,874 patients were included in the primary analysis (day 31–180 from randomization). The efficacy and safety outcomes were symptomatic recurrent VTE and major or clinically relevant non-major bleeding. Results The rates of recurrent VTE and bleeding events we…

0301 basic medicineMalevitamin K antagonistEXTERNAL VALIDATIONTime FactorsVitamin KWarfarin/therapeutic use030204 cardiovascular system & hematologyTHERAPYSeverity of Illness Indexlaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawRecurrenceAtrial FibrillationVitamin K/antagonists & inhibitorsStrokeRISKAtrial fibrillationHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedrisk assessment modelTIMEPREDICTSTreatment OutcomeAnticoagulants/therapeutic useResearch DesignANTICOAGULATION CONTROLFemaleLife Sciences & Biomedicinemedicine.drugHemorrhage/drug therapyAdultmedicine.medical_specialtyRandomizationmedicine.drug_classvenous thromboembolismHemorrhageRisk AssessmentSensitivity and SpecificityEDOXABAN03 medical and health sciencesDouble-Blind MethodVITAMIN-K ANTAGONISTSInternal medicinemedicineNONVALVULAR ATRIAL-FIBRILLATIONORAL ANTICOAGULANTHumansInternational Normalized RatioBlood CoagulationScience & Technologybusiness.industryquality of treatmentWarfarinAnticoagulantsmedicine.diseasewarfarinClinical trial030104 developmental biologyPeripheral Vascular DiseasechemistryBlood Coagulation/drug effectsAtrial Fibrillation/bloodCardiovascular System & CardiologyLinear ModelsWarfarinbusinessVenous Thromboembolism/drug therapyThrombosis and haemostasis
researchProduct

Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)

2021

Abstract Scope Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting. Methods The panel conducted a detailed review of the literature and eventual press rele…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)030106 microbiologyCoronavirupractice guidelines as topiccoronavirusrandomized controlled trials as topicGuidelinesmedicine.disease_causemedicallaw.invention03 medical and health sciences0302 clinical medicinesocietiesRandomized controlled triallawPandemicitalymedicinepneumonia030212 general & internal medicineIntensive care medicinehumansSocieties MedicalCoronavirustherapySARS-CoV-2business.industryCOVID-19; Coronavirus; Pneumonia; SARS-CoV-2; TherapyStandard treatmentCOVID-19PneumoniaGeneral Medicinecovid-19; coronavirus; pneumonia; sars-cov-2; therapy; covid-19; humans; italy; randomized controlled trials as topic; sars-cov-2; societies medical; standard of care; practice guidelines as topicCOVID-19 Drug TreatmentCoronavirusClinical trialsars-cov-2Infectious Diseasescovid-19standard of carePosition paperObservational studyTherapyCoronavirus; COVID-19; Pneumonia; SARS-CoV-2; TherapybusinessHuman
researchProduct

Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study)

2018

[Background]: While nutritional interventions with prebiotics and probiotics seem to exert immunological effects, their clinical implications in human immunodeficiency virus (HIV)–infected subjects initiating antiretroviral therapy (ART) at advanced HIV disease remain unclear.

0301 basic medicineMicrobiology (medical)medicine.medical_specialtySynbioticsCD4 T cellsPlaceboGastroenterologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialAcquired immunodeficiency syndrome (AIDS)lawInternal medicinemedicineImmunoactivation030212 general & internal medicineYoung adultAdverse effectInflammationbusiness.industrySurrogate endpointMicrobiotaProbioticsvirus diseasesmedicine.diseaseClinical trial030104 developmental biologyInfectious DiseasesbusinessClinical Infectious Diseases
researchProduct

An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy

2021

Background & aims: Hydroxychloroquine (HCQ) and chloroquine (CQ) are anti-malarial drugs frequently used in the rheumatologic field. They were recently identified as potential therapeutic options for Coronavirus Disease (COVID-19). The present study aims to map and grade the diverse health outcomes associated with HCQ/CQ using an umbrella review approach. Methods: Umbrella review of systematic reviews of observational and intervention studies. For observational studies, random-effects summary effect size, 95% confidence interval, and 95% prediction interval were estimated. We also assessed heterogeneity, evidence for small-study effect, and evidence for excess significance bias. The quality…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyhydroxychloroquine030106 microbiologyDiseaseReviewlcsh:Infectious and parasitic diseaseslaw.inventionchloroquine03 medical and health sciences0302 clinical medicinesystematic reviewRandomized controlled triallawChloroquineInternal medicineDiabetes mellitusChloroquine; COVID-19; Hydroxychloroquine; umbrella review; COVID-19; Chloroquine; Humans; Hydroxychloroquine; SARS-CoV-2medicineHumanslcsh:RC109-216030212 general & internal medicineumbrella reviewbusiness.industrySARS-CoV-2COVID-19HydroxychloroquineChloroquineGeneral Medicinemedicine.diseaseConfidence intervalCOVID-19 Drug TreatmentInfectious DiseasesSystematic reviewObservational studybusinessmedicine.drugHumanHydroxychloroquine
researchProduct

Shelf life evaluation of fresh-cut red chicory subjected to different minimal processes

2018

Abstract Microbiological, chemical and physical parameters of minimally processed red chicory (Cichorium intybus L.) subjected to two different transformation processes were investigated. A classic ready-to-eat (RTE) process (P1) and a production without cutting (P2) were monitored during refrigerated (4 °C) storage (15 d). Total mesophilic microorganisms, total psychrotrophic microorganisms and pseudomonads were detected at the highest cell densities in all samples. Presumptive Pseudomonas population dominated the cultivable microbial community of RTE red chicory and were characterized genetically. Twenty-two randomly amplified polymorphic DNA (RAPD) types were investigated by 16S rRNA gen…

0301 basic medicineMicroorganism030106 microbiologyPopulationShelf lifeSettore AGR/04 - Orticoltura E FloricolturaPseudomonaMicrobiologyChicory03 medical and health sciences0404 agricultural biotechnologyPseudomonasCichoriumVegetablesFood scienceeducationeducation.field_of_studybiologyPseudomonas; Ready-to-eat vegetables; Red chicory; Shelf life; Food Science; MicrobiologyPseudomonas04 agricultural and veterinary sciencesAscorbic acidbiology.organism_classification040401 food scienceRandom Amplified Polymorphic DNA TechniqueRAPDReady-to-eat vegetableFood StorageMicrobial population biologyRed chicoryFood ScienceMesophileSettore AGR/16 - Microbiologia Agraria
researchProduct

2017

Proteins containing glutamine repeats (polyQ) are known to be structurally unstable. Abnormal expansion of polyQ in some proteins exceeding a certain threshold leads to neurodegenerative disease, a symptom of which are protein aggregates. This has led to extensive research of the structure of polyQ stretches. However, the accumulation of contradictory results suggests that protein context might be of importance. Here we aimed to evaluate the structural context of polyQ regions in proteins by analysing the secondary structure of polyQ proteins and their homologs. The results revealed that the secondary structure in polyQ vicinity is predominantly random coil or helix. Importantly, the region…

0301 basic medicineMultidisciplinary030102 biochemistry & molecular biologybiologyChemistrySaccharomyces cerevisiaeStructural contextContext (language use)Protein aggregationbiology.organism_classificationRandom coilProtein–protein interactionCell biology03 medical and health sciences030104 developmental biologyProtein structureProtein secondary structurePLOS ONE
researchProduct

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

2016

IF 5.008; International audience; Anti-EGFR therapy and antiangiogenic therapies are used alone or in combination with chemotherapies to improve survival in metastatic colorectal cancer. However, it is unknown whether pretreatment with antiangiogenic therapy could impact on the efficacy of anti-EGFR therapy. We selected one hundred and twenty eight patients diagnosed with advanced colorectal cancer with a KRAS and NRAS unmutated tumor. These patients were treated with cetuximab or panitumumab alone or with chemotherapy as second or third-line. Univariate and multivariate Cox model analysis were performed to estimate the effect of a previous bevacizumab regimen on progression free survival a…

0301 basic medicineNeuroblastoma RAS viral oncogene homologOncologyMaleVascular Endothelial Growth Factor AColorectal cancerCetuximabAngiogenesis Inhibitorsmedicine.disease_causeTrialGTP PhosphohydrolasesRas mutations[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsDrug InteractionsAged 80 and overCetuximabPanitumumabAntibodies MonoclonalMiddle Aged3. Good healthErbB ReceptorsOncology030220 oncology & carcinogenesisFemaleKRASColorectal Neoplasms1st-Line treatmentmedicine.drugResearch PaperAdultSTAT3 Transcription Factormedicine.medical_specialtyBevacizumabAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologybevacizumabIrinotecanDisease-Free SurvivalTumor angiogenesisProto-Oncogene Proteins p21(ras)03 medical and health sciencesVEGFRInternal medicineCell Line TumormedicinePanitumumabHumansEndothelial growth-FactorChemotherapyProgression-free survivalAgedbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyMembrane Proteinsmetastatic colon cancerStat-3medicine.diseaseVascular Endothelial Growth Factor Receptor-2IrinotecanRandomized phase-III030104 developmental biologyanti-EGFR therapyFactor receptorCaco-2 Cellsbusiness
researchProduct